Anna Schwendeman

Vice President, Preclinical Development at ONL Therapeutics, Inc.

Anna Schwendeman

Anna Schwendeman

Vice President, Preclinical Development at ONL Therapeutics, Inc.

Overview
RelSci Relationships

64

Relationships
RelSci Relationships are individuals Anna Schwendeman likely has professional access to. A relationship does not necessarily indicate a personal connection.

President & Chief Executive Officer at ONL Therapeutics, Inc.

Relationship likelihood: Strong

Co-Founder at ONL Therapeutics, Inc.

Relationship likelihood: Strong

Co-Founder at ONL Therapeutics, Inc.

Relationship likelihood: Strong

Senior Vice President of Operational Excellence at ONL Therapeutics, Inc.

Relationship likelihood: Strong

Senior Vice President-Clinical Development & Operation at Cerenis Therapeutics Holding SA

Relationship likelihood: Average

Chief Operating Officer at Esperion Therapeutics, Inc.

Relationship likelihood: Average

Former Chemistry Director at Pfizer, Inc.

Relationship likelihood: Average

Co-Founder at Cerenis Therapeutics Holding SA

Relationship likelihood: Average

Vice President of Project Operations at ONL Therapeutics, Inc.

Relationship likelihood: Average

Co-Founder at Cerenis Therapeutics Holding SA

Relationship likelihood: Average

In The News
Orlando Sentinel (Florida)
July 10, 2015
DEATHS IN CENTRAL FLORIDA
PR Newswire
October 29, 2013
ONL Announces Leadership Changes
Paths to Anna Schwendeman
Potential Connections via
Relationship Science
You
Anna Schwendeman
Vice President, Preclinical Development at ONL Therapeutics, Inc.
Career History
Vice President, Preclinical Development
2013 - Current

ONL Therapeutics, Inc. develops biopharmaceutical services. It protects and improves the vision of patients with a range of retinal diseases and conditions, including retinal detachment and both the wet and dry forms of age-related macular degeneration. The company was founded by David Zacks and Jeffery Jamison in 2006 and is headquartered in Ann Arbor, MI.

Senior Director-Pharmaceutical Sciences
Prior

Cerenis Therapeutics Holding SA is a biopharmaceutical company, which engages in development of high density lipoprotein therapies for the treatment of cardiovascular and metabolic diseases. Its therapies consist of CER 001 and 209. The company was founded by Jean-Louis Dasseux on March 24, 2005 and is headquartered in Labege, France.

Director-Pharmaceutical Sciences
Prior

Esperion Therapeutics, Inc. is a clinical stage pharmaceutical company, which engages in the development and commercialization of oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). It offers Bempedoic acid and Ezetime combination pill as therapies that have been shown to lower elevated LDL-C levels in patients with hypercholesterolemia, including patients inadequately treated with current lipid-modifying therapies. The company was founded by Roger S. Newton and Charles L. Bisgaier on January 22, 2008 and is headquartered in Ann Arbor, MI.

Non-Profit Donations & Grants

Learn how non-profit organizations benefit from RelSci
$500 +
2011

THE ORGANIZATION SUPPORTS LOCAL FEEDING PROGRAMS THROUGHOUT WASHTENAW COUNTY THROUGH COLLECTION AND DELIVERY OF SURPLUS PERISHABLE FOOD FROM LOCAL SOURCES AND FROM THE ACQUISITION AND DISTRIBUTION OF NONPERISHABLE FOOD THROUGH A NATIONAL FOOD BANK PROGRAM.

$500 +
2010

THE ORGANIZATION SUPPORTS LOCAL FEEDING PROGRAMS THROUGHOUT WASHTENAW COUNTY THROUGH COLLECTION AND DELIVERY OF SURPLUS PERISHABLE FOOD FROM LOCAL SOURCES AND FROM THE ACQUISITION AND DISTRIBUTION OF NONPERISHABLE FOOD THROUGH A NATIONAL FOOD BANK PROGRAM.

Other Affiliations
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Anna Schwendeman. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Anna Schwendeman's profile does not indicate a business or promotional relationship of any kind between RelSci and Anna Schwendeman.